Agenus
(NASDAQ: AGEN today
announced results published from a Phase 2 study demonstrated that more
than 90% of the patients treated with Prophage Series G-200 were alive
at six months after surgery and 30% were alive at twelve months.
Additionally, the median overall survival was approximately eleven
months. This compares favorably to the expected median survival for
recurrent Glioblastoma multiforme (GBM) patients of three to nine months1-7.
The primary objective of this multi-center, single arm Phase 2 trial was
to assess the survival rate at six months.
The data was published in a manuscript in Neuro-Oncology, the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in